To the editor:

Thalidomide based therapy for multiple myeloma (MM) improves the response and the complete remission (CR) rates in previously untreated and relapsed/refractory MM (overall response rate was 48- 73% with a 5- 10% CR) \[[@B1],[@B2]\]. In this study, we performed a retrospective study of 42 newly diagnosed and relapsed/refractory MM patients treated with thalidomide based regimens without upfront ASCT at Ramathibodi Hospital during January 2005-October 2008. Thirteen and 29 patients were previously untreated and relapsed/refractory MM, respectively (Table [1](#T1){ref-type="table"}). Twenty-two patients received thalidomide 200 mg/day and oral dexamethasone 20- 40 mg/day (d1-4) every 2 weeks, 16 patients received oral melphalan 4 mg/m^2^/day (d1-7), prednisolone 40 mg/m^2^/day (d1-7) and thalidomide 100 mg/day every 4 weeks, 3 patients received thalidomide 200-400 mg/day and the remaining 1 patient received thalidomide 100 mg/day, pegylated liposomal doxorubicin i.v. 40 mg/m^2^/day (d1) and oral dexamethasone 40 mg/day (d1-4, 9-12) every 4 weeks. Eighty-eight percents (23/26 patients) achieving CR/VGPR (very good partial remission) received thalidomide maintenance therapy (100-200 mg/day). Aspirin 65- 325 mg/day or warfarin 1.5 mg/day was given to all patients for deep vein thrombosis prophylaxis. Of the 41 evaluable patients, median treatment period was 21 months (3- 45 m). The ORR (overall response rate) was 92.7%, with a 63.4% CR/VGPR. Median number of courses to achieve PR and CR/VGPR were 4 (range, 2-13) and 6 courses (range, 2-16), respectively. There was no difference in ORR and CR between frontline and salvage therapy groups (92.3% vs 93%) and (39% vs 23%), respectively. The ORR and CR rate for those treated with thal/dex were slightly higher than those treated with MPT (95.2% vs 87.5% and 38% vs 25%). Median follow up was 23 months, 3-year-OS and 3-year-PFS were 72.6 and 58.6%, respectively. Median TTP was 42 months, non- VGPR/CR patients had significant poorer PFS by multivariate analysis (*p*= 0.01) and non-responders had significant shorter OS (*p*= 0.01). In maintenance group, median treatment duration was 14 months (4-37 m). Three-year-PFS and 3-year-OS were 67 and 80%, respectively. Toxicities were constipation (81%), neuropathy (67%), muscle weakness in the legs (5%), infection (7%) and thrombosis (5%). New agents for treatment of MM with no planned ASCT show the CR/VGPR rates of 50- 80% with a PFS of 2 years \[[@B3]-[@B5]\]. The CR/VGPR rates in our patients were also high that might be associated with a prolonged use of thalidomide induction. Thalidomide maintenance in CR/VGPR patients provided impressive survival benefit. Hence, thalidomide is an effective therapy for MM and prolonged thalidomide use had the survival benefit and had minimal serious toxicity in non-transplant MM patients. To date, MM remains incurable. Novel agents continue to be developed and are eagerly awaited \[[@B5]-[@B7]\].

###### 

Patients\' characteristics and treatment outcomes of previously untreated and relapsed/refractory multiple myeloma

                                              ORR        CR/VGPR   PFS        OS                                                    
  ------------------------------ ------------ ---------- --------- ---------- ------ ------ ------------ ------ ------ ------------ ------
  Age (years), median (range)    62,(36-75)                                                                                         
   ≤ 60                          17           15(94)     0.83      9(56.3)    0.45   2.95   0.98-8.81    0.05   0.81   0.09-7.27    0.85
   \> 60                         25           23(92)               17(68)                                                           
                                                                                                                                    
  Sex                                                                                                                               
   Male                          21           18(85.7)   0.79      13(65)     0.91   0.77   0.25-2.38    0.65   2.06   0.34-12.68   0.44
   Female                        21           20(95.2)             14(66.7)                                                         
                                                                                                                                    
  Prior treatment                                                                                                                   
   Yes                           29           26(92.6)   0.95      19(67.9)   0.69   3.68   0.91-10.28   0.06   0.87   0.96-7.88    0.9
   No                            13           12(92.3)             8(61.5)                                                          
                                                                                                                                    
  International staging system                                                                                                      
   I, II                         8, 18        24(92.3)   0.97      15(57.7)   0.93   6.30   0.73-54.01   0.09   2.22   0.20-24.57   0.51
   III                           13           12(92.3)             8(61.5)                                                          
   No data                       3                                                                                                  
                                                                                                                                    
  M-protein subtype                                                                                                                 
   IgG, IgA, IgM                 23, 8, 1     27(87.1)   0.32      19(61.3)   0.86   3.19   0.64-15.91   0.16   1.21   0.13-11.65   0.87
   Kappa, Lamda                  3, 6         9(100)               6(66.7)                                                          
   Unknown type                  1                                                                                                  
                                                                                                                                    
  Serum creatinine level                                                                                                            
   \< 2 mg/dl                    34           31(91.2)   0.43      22(64.7)   0.57   0.74   0.08-6.72    0.79   0.03   0.01-856.9   0.50
   ≥ 2 mg/dl                     8            7(100)               4(57.2)                                                          
                                                                                                                                    
  Serum β2 M level, μg/ml                                                                                                           
   ≤ 5                           26           24(92.3)   0.53      17(65.4)   0.79   4.89   0.55-43.88   0.16   1.97   0.18-21.81   0.58
   \> 5                          13           11(84.6)             8(61.5)                                                          
   No data                       3                                                                                                  
                                                                                                                                    
  Response to treatment                                                                                                             
   Yes                           38           \-         \-        \-         \-     0.15   0.04-0.61    0.01   0.03   0.01-0.35    0.01
   No                            3                                                                                                  
                                                                                                                                    
  CR/VGPR                                                                                                                           
   Yes                           26           \-         \-        \-         \-     0.14   0.04-0.47    0.01   0.21   0.03-1.48    0.12
   No                            15                                                                                                 
